Meta AnalysisID 4608
对已接受甲状腺切除术和放射性碘治疗的分化型甲状腺癌患者，测量甲状腺球蛋白和甲状腺球蛋白抗体(伴或不伴放射性同位素扫描)以评估残留或复发疾病的临床和成本效果
CRD42021282429
For people who have had thyroidectomy and radioactive iodine for differentiated thyroid cancer, what is the clinical and cost effectiveness of measuring thyroglobulin and thyroglobulin antibodies (with or without radiois
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4608
- Evidence Id
- 13166
- Core Evidence Id
- 13166
- Source Meta Analysis Id
- 4575
- Herb2 Meta Analysis Id
- HBMA004575
- Crd Id
- CRD42021282429
- Title
- The clinical and cost effectiveness of measuring thyroglobulin and thyroglobulin antibodies (with or without radioisotope scans) to assess residual or recurrent disease, for people who have had thyroidectomy and radioactive iodine treatment for differentiated thyroid cancer
- Review Question
- For people who have had thyroidectomy and radioactive iodine for differentiated thyroid cancer, what is the clinical and cost effectiveness of measuring thyroglobulin and thyroglobulin antibodies (with or without radioisotope scans) to assess residual or recurrent disease?
- Study Type Included
- • Systematic reviews • RCTs Non-randomised studies will be excluded.
- Condition Being Studied
- Thyroid Cancer
- Participant
- Inclusion: People aged 16 or over who have had thyroidectomy and radioactive iodine treatment for differentiated thyroid cancer. People will need to have had their first assessment with thyroglobulin between 3 and 6 months after ablation. If <3 months or 6 months -1 year, downgrading for population indirectness will occur. Exclusion: Children under 16 First thyroglobulin assessment >1 year post-ablation
- Animal
- Human Disease Modelled
- Intervention
- • Measurement of thyroglobulin and thyroglobulin antibodies with radioisotope scans • Measurement of thyroglobulin and thyroglobulin antibodies without radioisotope scans • Measurement of thyroglobulin and thyroglobulin antibodies without clear indication of radioisotope scans (in terms of description in paper)
- Comparator Control
- Each other Usual care (except thyroglobulin) / Ultrasound [Therefore, this question attempts to ask two questions in one: 1) whether thyroglobulin measurement is useful compared to usual care or ultrasound, and 2) whether radioisotope scans affect this usefulness (if any)?]
- Main Outcome
- • mortality • quality of life • local cancer progression • incidence of distant metastases • detection of residual disease or detection of recurrent disease when no residual disease seen Time of follow up: longest available Measures of effect Relative risks for the binary outcomes and mean difference for quality of life
- Outcome Measure
- Additional Outcome
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Adenocarcinoma; Autoantibodies; Cost-Benefit Analysis; Humans; Iodine Radioisotopes; Radionuclide Imaging; Thyroglobulin; Thyroid Function Tests; Thyroid Neoplasms; Thyroidectomy; anti-thyroglobulin
- Contact
- Mark Perry [email protected]
- Organisational Affiliation
- National Guideline Centre
- Funding Source
- NICE
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-09-29
- Registration Date
- 2021-10-01
- Anticipated Start Date
- 2021-09-30
- Anticipated Completion Date
- 2021-10-30
- Title Cn
- 对已接受甲状腺切除术和放射性碘治疗的分化型甲状腺癌患者，测量甲状腺球蛋白和甲状腺球蛋白抗体(伴或不伴放射性同位素扫描)以评估残留或复发疾病的临床和成本效果
- Title En
- The clinical and cost effectiveness of measuring thyroglobulin and thyroglobulin antibodies (with or without radioisotope scans) to assess residual or recurrent disease, for people who have had thyroidectomy and radioactive iodine treatment for differentiated thyroid cancer
- Bilingual Status
- complete